Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model

Hyperprogression upon immunotherapy: A chance for (hyper-)progress

(2020) Roch Houot et al.   EUROPEAN JOURNAL OF CANCER

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

(2019) Akinori Sasaki et al.   Gastric Cancer

Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function

(2019) Catherine Konopacki et al.   NATURE IMMUNOLOGY

Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist

(2019) G.R. Ferretti et al.   Diagnostic and Interventional Imaging

The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination

(2019) Kenichi Suda   Journal of Thoracic Disease

PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!

(2019) Paul Hofman   Journal of Thoracic Disease

Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment

(2019) Concetta Elisa Onesti et al.   Journal of Thoracic Disease

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report

(2019) Ilke Tunali et al.   LUNG CANCER

Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties

(2019) Roland G Stein et al.   CANCER RESEARCH

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities

(2019) Yada Kanjanapan et al.   CANCER

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

(2019) C G Kim et al.   ANNALS OF ONCOLOGY

Hyperprogression under Immunotherapy

(2019) Frelaut et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploring the emerging role of the microbiome in cancer immunotherapy

(2019) Jessica Fessler et al.   Journal for ImmunoTherapy of Cancer

Hyperprogression during immunotherapy: do we really want to know?

(2019) S Champiat et al.   ANNALS OF ONCOLOGY

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

(2019) Erich Sabio et al.   Genome Medicine

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

(2019) Erick Riquelme et al.   CELL

Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development

(2019) Christophe Dumet et al.   mAbs

Hyperprogressive disease with immunotherapy: new directions

(2019) Sally C. M. Lau et al.   Journal of Thoracic Disease

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

(2019) Daniel A. Rauch et al.   BLOOD

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy

(2019) Komugi Okeya et al.   INTERNAL MEDICINE

Gut microbiome and cancer immunotherapy

(2019) Jin‐Yu Sun et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

(2019) Weiting Qin et al.   Frontiers in Immunology

Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming

(2019) Edina Gyukity-Sebestyén et al.   Frontiers in Immunology

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis

(2019) Jong Yeob Kim et al.   Cancers

Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?

(2019) R. Califano et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab Interferes with the Differentiation of Human FOXP3+–Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR

(2019) Varun Sasidharan Nair et al.   JOURNAL OF IMMUNOLOGY

Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer

(2019) Stergios Doumas et al.   ORAL ONCOLOGY

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

(2019) Guillaume Manson et al.   Journal for ImmunoTherapy of Cancer

Structure and Optimization of Checkpoint Inhibitors

(2019) Sarah L. Picardo et al.   Cancers

PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation

(2018) Xin Yao Qiu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hyperprogression as a Distinct Outcome after Immunotherapy

(2018) J. Fuentes-Antrás et al.   CANCER TREATMENT REVIEWS

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy

(2018) Jonathan S. Kurman et al.   Journal of Thoracic Disease

Do immune checkpoint inhibitors need new studies methodology?

(2018) Roberto Ferrara et al.   Journal of Thoracic Disease

Immunotherapy in the Asiatic population: any differences from Caucasian population?

(2018) Lunxi Peng et al.   Journal of Thoracic Disease

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

(2018) Shisuo Du et al.   OncoImmunology

Abstract LB-115: Tumor intrinsic PD-1/PD-L1 signalling induces mesenchymal to epithelial transition in canine osteosarcoma cells

(2018) Maciej Parys et al.   CANCER RESEARCH

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

(2018) Yelena Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

(2018) Han Yao et al.   Frontiers in Immunology

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

1211PHyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?

(2018) E Farè et al.   ANNALS OF ONCOLOGY

54PDPre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression

(2018) M Zuazo et al.   ANNALS OF ONCOLOGY

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism

(2018) David A. Knorr et al.   CLINICAL CANCER RESEARCH

Hyperprogressive disease: recognizing a novel pattern to improve patient management

(2018) Stéphane Champiat et al.   Nature Reviews Clinical Oncology

The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells

(2018) Sayantani Ghosh et al.   Nature Communications

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

(2018) Giuseppe Lo Russo et al.   CLINICAL CANCER RESEARCH

Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice

(2017) Vassil Dimitrov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

PD-1 and PD-L1 expression in bone and soft tissue sarcomas

(2017) Alireza Torabi et al.   PATHOLOGY

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

(2017) Veronica Huber et al.   SEMINARS IN CANCER BIOLOGY

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells

(2017) Yunfei Liao et al.   Oncotarget

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

(2016) M. F. Sanmamed et al.   ANNALS OF ONCOLOGY

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma

(2016) Curtis A. Clark et al.   CANCER RESEARCH

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing

(2016) Judith Balmaña et al.   JOURNAL OF CLINICAL ONCOLOGY

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

(2015) Shari Pilon-Thomas et al.   CANCER RESEARCH

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

How Drugs are Developed and Approved by the FDA: Current Process and Future Directions

(2014) Arthur A Ciociola et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

(2014) Vassiliki A. Boussiotis et al.   CANCER JOURNAL

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display

(2014) Christian Schröter et al.   mAbs

The cellular and molecular origin of tumor-associated macrophages

(2014) R. A. Franklin et al.   SCIENCE

Impact of aging in cancer immunotherapy

(2014) Myriam N Bouchlaka et al.   OncoImmunology

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic responses in mouse models poorly mimic human inflammatory diseases

(2013) Junhee Seok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cohabiting family members share microbiota with one another and with their dogs

(2013) Se Jin Song et al.   eLife

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia

(2011) S. Zhou et al.   MOLECULAR AND CELLULAR BIOLOGY

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis

(2010) Iglika K. Djoumerska-Alexieva et al.   FEBS Journal

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1

(2010) M. Ghiotto et al.   INTERNATIONAL IMMUNOLOGY

Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression

(2009) Melissa Paoloni et al.   BMC GENOMICS

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Mouse xenograft models vs GEM models for human cancer therapeutics

(2008) A. Richmond et al.   Disease Models & Mechanisms